Home » Topics » Disease categories and therapies » Urology

Urology
RSS

TheraTech joins forces with Meiji and Sankyo to develop and market oxybutynin patch

Oct. 10, 1997

Unique profile described for Glaxo Wellcome's 5alpha-reductase inhibitor

Oct. 8, 1997

Empi's new incontinence device approved by FDA; worldwide launch slated for January

Oct. 7, 1997

Development of YM-46303 stopped

Oct. 2, 1997

Interstim approved for marketing in U.S.

Oct. 1, 1997

Alza to market IVAX urology products in U.S., Canada

Sep. 30, 1997

Bosentan evaluated in humans for preventing ciclosporin nephrotoxicity

Sep. 29, 1997

Synaptic focuses on dihydropyrimidinones for BPH

Sep. 29, 1997

Sildenafil continues to demonstrate efficacy in treating ED

Sep. 26, 1997

Design, synthesis and evaluation of SNAP-5582 derivatives for BPH

Sep. 26, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 29, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
Will Ovid’s golden age of KCC2 metamorph CNS?
BioWorld
The “deep dive” April 8 by Ovid Therapeutics Inc. into potassium-chloride co-transporter 2 (KCC2) research included company officials and independent experts in...
BMS-Hengrui deal strikes panic in Washington
BioWorld
On the heels of the multibillion-dollar licensing deal between Bristol Myers Squibb Co. and Jiangsu Hengrui Pharmaceuticals Co. Ltd., Chairman John Moolenaar...